Extensively Drug-Resistant Tuberculosis: A Sign of the Times and an Impetus for Antimicrobial Discovery.
Extensively Drug-Resistant Tuberculosis: A Sign of the Times and an Impetus for Antimicrobial Discovery.
复制标题
DOI：
10.3390/ph3072268
复制
发表时间：
2010-07-01
期刊：
影响因子：
--
通讯作者：
Haydel SE
中科院分区：
文献类型：
--
作者：
Haydel SE
结核分枝杆菌是一种非常成功的人类病原体，感染了世界三分之一的人口，每年造成近200万人死亡。在这篇文章中，讨论了当前全球结核病（TB）发病率、患病率和死亡率的趋势，沿着标准的TB治疗方案、一线和二线抗结核药物的特点和抗生素耐药性的机制。广泛耐药（XDR）结核菌株对我们最好的抗生素具有耐药性，而且很难治疗，这进一步加剧了全球结核病紧急情况。本文还重点介绍了广泛耐药结核菌株的出现、全球健康影响以及广泛耐药结核病的现有治疗方案和结果。最后，本文简要介绍了目前正在进行II期临床评价的抗结核新药，以及发现针对耐药结核分枝杆菌的新抗菌化合物的动力。结核病和改善结核病治疗。
Mycobacterium tuberculosis is an extraordinarily successful human pathogen, infecting one-third of the world’s population and causing nearly two million deaths each year. In this article, current trends in worldwide tuberculosis (TB) incidence, prevalence, and mortality are discussed along with standard TB treatment regimens, characteristics of first-line and second-line anti-tuberculosis drugs, and mechanisms of antibiotic resistance. The global TB emergency has been further exacerbated by extensively drug-resistant (XDR) TB strains that are resistant to our best antibiotics and very difficult to treat. This review also focuses on the emergence of XDR-TB strains, the global health impact, and existing treatment options and outcomes for XDR-TB disease. Finally, this review briefly describes new anti-tuberculosis drugs currently in Phase II clinical evaluations and the impetus for discovering new antibacterial compounds to target drug-resistant M. tuberculosis and improve tuberculosis therapy.